The normal aortic valve has three leaflets that open and close to control the flow of blood into the aorta from the left ventricle of the heart as it beats. In contrast, a bicuspid aortic valve, or BAV, has only two leaflets. With this malformation, the valve doesn’t function perfectly, however, it may function adequately for years with no symptoms or obvious signs of a problem. Depending on the degree of malformation, blood flowing through the valve may make an abnormal sound, or a murmur. While some bicuspid aortic valves are silent, the detection of a murmur may be the first indication of bicuspid aortic valve disease.
Medical Services related to Matthew Augustin Romano MD
The top-ranked hospital in Michigan for heart and heart surgery programs, the University of Michigan Cardiovascular Center performs more than 2,000 heart operations annually, sees approximately 3,500 outpatients each year, and delivers a team of experts to make our patients' hospital stay both comfortable and successful.
Frequently asked questions about TAVR, including the definition, advantages and recovery information.
The University of Michigan offers the state's only accredited heart failure disease management program, with medical and surgical care, heart-assisting technology and comprehensive rehabilitation programs.
Heart transplant is one of a number of options for severe heart disease. It's not for everyone, and should not be considered unless all other viable treatment options have been unsuccessful. At the University of Michigan Heart Transplant Program, our closely integrated team of cardiac transplant surgeons and transplant cardiologists are able to treat and implant donor hearts in the sickest of patients because of our high volume, vast experience and active research program.
VADs (ventricular assist devices) are mechanical devices that help your heart pump blood to the rest of your body when other methods don't relieve heart failure symptoms. LVADs, the most common type of VAD, are used to support the left side of the heart, but RVADs may be used to support the right side of the heart as well. The University of Michigan Frankel Cardiovascular Center is home to one of the largest VAD programs in the country, and is one of only a few institutions worldwide that has access to many investigational and FDA-approved mechanical circulatory support devices.
The VAD Program at the University of Michigan offers one of the nation's most comprehensive programs in the area of treatment for severe chronic or acute heart failure. This goes beyond conventional treatment, giving patients access to a broad variety of state-of-the-art options of circulatory support devices and skilled post-implantation care.
The MitraClip procedure is used to treat patients who have symptoms because of mitral regurgitation. The MitraClip procedure does not require opening the chest or temporarily stopping your heart (cardiopulmonary bypass). Instead, doctors access your heart through a vein in your leg to repair your mitral valve. The MitraClip procedure may be an option for patients with mitral regurgitation who are too sick for surgery or considered too high risk.
The mitral valve controls the flow of blood going in one direction from the lungs to the body. If the valve does not close properly, or open completely, the heart may have to work twice as hard to do its job, which can lead to life threatening heart conditions. Frankel Cardiovascular Center heart doctors offer advanced mitral valve treatments that can't be found at other hospitals because of U-M's involvement in clinical trials.
Treatment options for mitral valve disease include medication therapy, open-heart surgery, and minimally invasive procedures, both surgical and transcatheter. Performing these repairs early in the disease process before a patient's mitral valve disease progresses into advanced heart conditions such as congestive heart failure, atrial fibrillation, and pulmonary hypertension is our top priority.
TAVR stands for Transcatheter Aortic Valve Replacement, a minimally invasive, catheter-based procedure to replace the diseased aortic valve in patients with severe aortic stenosis. Aortic stenosis is a condition in which the aortic valve does not open fully due to a thickening of the valve leaflets, often caused by a buildup of calcium on the leaflets. This thickening makes it difficult for the leaflets to open and close, which decreases blood flow from the heart to the body. The condition may cause the heart to work harder to pump blood. For decades, open heart surgical aortic valve replacement (SAVR) has been the standard treatment for severe aortic stenosis, but in the past few years TAVR has rapidly replaced SAVR in high-risk patients as well as patients at moderate risk for surgery. This is due to excellent clinical trial results showing equal or better patient outcomes compared to SAVR. Most recently, in August of 2019, TAVR was approved for patients at low risk for surgery. These low-risk patients, whose aortic stenosis would typically receive an open-heart surgical aortic valve replacement, can now be considered a candidate for a TAVR procedure.